Alzamend Neuro Inc

NASDAQ:ALZN   10:46:13 AM EDT
1.39
+0.01 (+0.72%)
Products, Regulatory

Alzamend Neuro Announces Positive Topline Data From Phase 1 First-In-Human Clinical Trial For AL001 Treatment Of Dementia Related To Alzheimer's

Published: 12/17/2021 14:14 GMT
Alzamend Neuro Inc (ALZN) - Alzamend Neuro Announces Positive Topline Data From Phase 1 First-in-human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer's.
Alzamend Neuro - Look Forward to Initiating Phase 2 Multiple Ascending Dose Study Involving Alzheimer's Patients in Q2 of 2022.
Alzamend Neuro - Pursuing Ind Applications With U.S. FDA During 2022 for Bipolar Disorder, Depression, & Post-traumatic Stress Disorder Indication.